Clinical trial
A Parallel-group Treatment, Proof-of-concept Phase 2, Multicenter, Double-blind, Randomized Two-arm Clinical Trial to Investigate the Efficacy and Safety of Subcutaneous NT 201 Injections Compared With Placebo Injections in Decreasing Pain Intensity in Male and Female Participants Aged 18 Years and Older With Moderate to Severe Chronic Peripheral Neuropathic Pain Due to Postherpetic Neuralgia or Peripheral Nerve Injury
NCT06091020 is registered in ClinicalTrials.gov with Merz Therapeutics GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Parallel-group Treatment, Proof-of-concept Phase 2, Multicenter, Double-blind, Randomized Two-arm Clinical Trial to Investigate the Efficacy and Safety of Subcutaneous NT 201 Injections Compared With Placebo Injections in Decreasing Pain Intensity in Male and Female Participants Aged 18 Years and Older With Moderate to Severe Chronic Peripheral Neuropathic Pain Due to Postherpetic Neuralgia or Peripheral Nerve Injury
- Lead sponsor
- Merz Therapeutics GmbH
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 22, 2023
- Completion date
- July 4, 2025
- Enrollment
- 123 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.
moderate to severe chronic peripheral neuropathic pain (pnp) due to postherpetic neuralgia (phn) or peripheral nerve injury